To Recruit for Diverse Alzheimer Trials, Go to the People
Most participants in AD research studies and trials are non-Hispanic whites. At a conference in St. Louis, scientists discussed strategies to include diverse populations.
ALL NEWS
6562 RESULTS
Sort By:
- Most Recent
- Most Commented
From St. Louis to Boston, Scientists Grapple with Ethnoracial Divide in AD Biomarkers
Across several studies, black/African Americans and Hispanic or Latino people had lower amyloid positivity rates than whites. Scientists are studying why.
2nd Symposium on Lipids in Brain Diseases
Cutting (or Slippery?) Edge: Lipids in Neurodegeneration Science Does the Brain Use Microglia to Maintain Its Myelin? Cracking the Cholesterol-AD Code: Metabolites and Cell Type Can Flipping a Lipid Switch Protect the Brain? The average human brain contai
Paper Alert: Those Fibrils Floating in Brain Fluid Are Toxic
They can be neutralized by lecanemab, an anti-amyloid antibody designed to mop up Aβ protofibrils.
After Long Wait, Aβ Oligomer Detangler Poised for Phase 2
Phase 1b results tease that the small molecule PRI-002 might curb cognitive decline. Phase 2 is slated for early 2024.
Gene Links Childhood Neurodegeneration to Mitophagy
Children lacking a gene needed for clearing away tired mitochondria develop a rare neurodegenerative disorder.
Biomarkers and Efficacy: Not (Yet?) a Perfect Union
Scientists at AAIC debated discrepant results, updated a model of the biomarker-efficacy relationship, and debuted the CenTauR scale for tau PET.
New Alzheimer’s Diagnostic Criteria Remain ‘Research Only’
This clarification comes after geriatricians argued that diagnosing AD in people without symptoms is premature, and the NIH pulled its name.
Clinical Trials on Alzheimer's Disease (CTAD) 2023- 16th
To Recruit for Diverse Alzheimer Trials, Go to the People From St. Louis to Boston, Scientists Grapple with Ethnoracial Divide in AD Biomarkers Treat Before ‘Aβ Bothers Tau,’ Scientists Say at CTAD Moving Forward: RNA-Targeted Attempts at Taking Down Tau,
Putting Palmitate on Synaptotagmin-11 Stymies α-Synuclein Tetramers
The fatty acid shields Syt11 from degradation. With more of it around, α-synuclein monomers cling to membranes.
Polygenic Scores Point to Microglia, Astrocytes in Alzheimer's Pathogenesis
Cell-type-specific polygenic risk scores single out microglia as influencers of Aβ and tau pathology, as well as cognitive decline.
Holloway Summit 2023: FTD Biomarkers
Second Holloway Summit Showcases Intense Search for FTD Biomarkers At Holloway Summit, FTD Imaging Shows New Vista To enable clinical trials in frontotemporal dementia, scientists need biomarkers that distinguish its several underlying pathologies. At a r
New Atlas Charts Mouse Brain in Exquisite Detail
Researchers wrangled gene expression, epigenetic, and spatial transcriptomic data on 32 million brain cells into the most detailed picture of the mouse brain yet.
Synuclein Assay Passes the Sniff Test—What of Other Seeds?
Analysis of cerebrospinal fluid from the Parkinson’s Progression Markers Initiative identifies PD with high sensitivity and specificity.
Copper Mountain: Death and Trophin Receptors—New Insight, New Drugs?
Death and taxes are reputedly inevitable, though death and receptors may be more interesting to Alzforum readers...
Current Filters
No filters selected